

1 **Main Manuscript for**

2 **Efficacy of a Spatial Repellent for Control of Aedes-Borne Virus**  
3 **Transmission: A Cluster Randomized Trial in Iquitos, Peru**

4 Amy C. Morrison, Ph.D.<sup>1,2+</sup>, Robert C. Reiner Jr., Ph.D.<sup>3+</sup>, William H. Elson, M.B.B.S.<sup>4</sup>, Helvio  
5 Astete, M.S.<sup>2</sup>, Carolina Guevara, M.S.<sup>2</sup>, Clara del Aguila, B.S.<sup>5</sup>, Isabel Bazan, M.D.<sup>2</sup>, Crystyan  
6 Siles, M.D.<sup>2</sup>, Patricia Barrera, M.S.<sup>2</sup>, Anna B. Kawiecki, M.S.<sup>1</sup>, Christopher M. Barker, Ph.D.<sup>1</sup>,  
7 Gissella M. Vasquez, Ph.D.<sup>6</sup>, Karin Escobedo-Vargas, B.S.<sup>6</sup>, Carmen Flores-Mendoza, Ph.D.<sup>6</sup>,  
8 Alfredo A. Huaman, B.S.<sup>2</sup>, Mariana Leguia, Ph.D.<sup>7</sup>, Maria E. Silva, Ph.D.<sup>2</sup>, Sarah A. Jenkins,  
9 Ph.D.<sup>2</sup>, Wesley R. Campbell, M.D.<sup>2</sup>, Eugenio J. Abente, Ph.D.<sup>2</sup>, Robert D. Hontz, Ph.D.<sup>2</sup>, Valerie  
10 A. Paz-Soldan, Ph.D.<sup>8</sup>, John P. Grieco, Ph.D.<sup>9</sup>, Neil F. Lobo, Ph.D.<sup>9+</sup>, Thomas W. Scott, Ph.D.<sup>4+</sup>,  
11 and Nicole L. Achee, Ph.D.<sup>9+</sup>

12 <sup>1</sup>Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine,  
13 University of California, Davis, CA, 95616 USA

14 <sup>2</sup>Department of Virology and Emerging Infectious Diseases, U.S. Naval Medical Research Unit  
15 No. 6, Lima, Peru, 3230 Lima Pl., Washington DC, 20521-3230

16 <sup>3</sup>Department of Health Metrics Sciences, University of Washington, Seattle, 98195 WA, USA

17 <sup>4</sup>Department of Entomology and Nematology, University of California, Davis, CA, 95616 USA

18 <sup>5</sup>Dirección General de Saneamiento Ambiental, Calle Alzamora 410, Iquitos, Peru

19 <sup>6</sup> Department of Entomology, U.S. Naval Medical Research Unit No. 6, Lima, Peru

20 <sup>7</sup>Genomics Laboratory, Pontificia Universidad Católica del Perú, Av. Universitaria 1801, San  
21 Miguel, Lima, Peru, 15000

22 <sup>8</sup>Department of Global Community Health and Behavioral Sciences, Tulane School of Public  
23 Health and Tropical Medicine, New Orleans, LA, 70112 USA

24 <sup>9</sup>Department of Biological Sciences, Eck Institute for Global Health, University of Notre Dame,  
25 239 Galvin Life Sciences Center. Notre Dame, IN, 46556 USA

26 **\*Indicates equal seniority**

27 **\*Corresponding Author:**

28 Nicole L. Achee, PhD

29 Department of Biological Sciences

30 239 Galvin Life Sciences Center

31 Notre Dame, IN, 46556 USA

32 **Email:** [nachee@nd.edu](mailto:nachee@nd.edu) **Phone:** 1-574-651-1561

33 **Author Contributions:** The trial was conceived and designed by NLA, ACM, RCR, JPG, NFL and  
34 TWS; data were gathered by the field team in Iquitos (ACM, WHE, HA, IB, CS, and ABK);  
35 laboratory testing by CG, PB, and AH; insecticide resistance testing by GMV, KEV, and CFM; and  
36 human use issues were managed by ACM, SAJ, and WRC. ML developed a Zika virus PCR assay  
37 used in the study. CDA provided Ministry of Health entomological information and coordinated  
38 activities with Iquitos field teams. The NAMRU-6 supervisory team in Lima included MS, SAJ,  
39 WRC, EJA, and RDH. CMB provided data management and ZIKV MNT laboratory testing.  
40 Statistical analysis was conducted by RCR. The first draft of the manuscript was written by ACM,  
41 RCR, TWS, and NLA, with revision following comments from all the authors.

42

43 **Disclosure Statement:** Approved for Public Distribution

44 **Competing Interest Statement:** The authors have declared that no competing interests exist.

45 **Copyright statement:** SAJ, WRC, EJA and RDH are military service members and ACM, HA,  
46 CG, IB, CS, GMV, KE, CF, AAH, and MES are employees of the U.S. Government. This work  
47 was prepared as part of their official duties. Title 17 U.S.C. §105 provides that “Copyright  
48 protection under this Title is not available for any work of the United States Government”. Title 17  
49 U.S.C. §101 defines a U.S. Government work as a work prepared by a military service member or  
50 employee of the U.S. Government as part of that person’s official duties.

51 **Disclaimer:** The views expressed in this article are those of the author and do not necessarily  
52 reflect the official policy or position of the Department of the Navy, Department of Defense, nor  
53 the U.S. Government.

54  
55 **Preprint Server:** A version of this manuscript was deposited as a medRxiv preprint doi:  
56 <https://doi.org/10.1101/2021.03.03.21252148>; posted August 3, 2021. It is made available under  
57 a CC-BY 4.0 International license.

58 **Classification:** Biological Sciences and Applied Biological Sciences.

59 **Keywords:** vector control, *Aedes aegypti*, spatial repellent, arbovirus vector, clinical trial

60 **This PDF file includes:**

61 Main Text  
62 Figures 1 to 5  
63 Tables 1 to 3  
64

## 65 Abstract

66 Over half the world's population is at risk for viruses transmitted by *Aedes* mosquitoes, such as,  
67 dengue and Zika. The primary vector, *Aedes aegypti*, thrives in urban environments. Despite  
68 decades of effort, cases and geographic range of *Aedes*-borne viruses (ABV) continue to expand.  
69 Rigorously proven vector control interventions that measure protective efficacy against ABV  
70 diseases is limited to *Wolbachia* in a single trial in Indonesia, and do not include any chemical  
71 intervention. Spatial repellents, a new option for efficient deployment, are designed to decrease  
72 human exposure to ABV by releasing active ingredients into the air that disrupt mosquito-human  
73 contact. A parallel, cluster-randomized controlled trial was conducted in Iquitos, Peru to quantify  
74 the impact of a transfluthrin-based spatial repellent on human ABV infection. From 2,907  
75 households across 26 clusters (13 per arm), 1,578 participants were assessed for seroconversion  
76 (primary endpoint) by survival analysis. Incidence of acute disease was calculated among 16,683  
77 participants (secondary endpoint). Adult mosquito collections were conducted to compare *Ae.*  
78 *aegypti* abundance, blood-fed rate and parity status through mixed effect difference-in-difference  
79 analyses. The spatial repellent significantly reduced ABV infection by 34.1% (1-sided 95% CI  
80 lower limit, 6.9%; 1-sided p-value=0.0236, z=1.98). *Aedes aegypti* abundance and blood-fed  
81 rates were significantly reduced by 28.6% (95% CI 24.1%, ∞); z=-9.11) and 12.4% (95% CI 4.2%,  
82 ∞); z=-2.43), respectively. Our trial provides the first conclusive statistical evidence from a pre-  
83 planned cluster randomized controlled clinical trial with a pre-defined effect size on the primary  
84 endpoint that was appropriate powered to prospectively quantify and statistically test for a  
85 difference in the impact of a chemical intervention, in this case a spatial repellent, to reduce the  
86 risk of ABV transmission compared to a placebo.

## 87 Significance Statement

88 Vector interventions are needed for *Aedes*-borne viral diseases (dengue, Zika, chikungunya, and  
89 yellow fever) prevention, but their application is hindered by the lack of evidence proving they  
90 prevent infection or disease. Our research reports the first conclusive statistical evidence from a  
91 pre-planned, prospective cluster-randomized, controlled clinical trial (cRCT) of significant  
92 protective efficacy (34.1% hazard estimate) against human *Aedes*-borne virus (ABV) infection by  
93 a chemical-based vector control intervention, the most commonly used intervention category  
94 among all ABV World Health Organization recommendations. A previous trial against malaria in  
95 Indonesia indicated a positive trend but did not detect a significant effect. Results from our ABV  
96 study will help guide public health authorities responsible for operational management and world-  
97 wide prevention of ABV, and incentivize new strategies for disease prevention.

## 98 99 Main Text

### 100 101 Introduction

102 *Aedes*-borne viral diseases (ABVD) [e.g., dengue (DENV), chikungunya (CHIKV), Zika (ZIKV),  
103 and yellow fever (YFV)] are devastating, expanding global public health threats that  
104 disproportionately affect low- and middle-income countries. Dengue, one of the most rapidly  
105 increasing vector-borne infectious diseases, results in ~400 million infections each year [1,2], with  
106 four billion people at risk of infection annually [3]. Currently, the primary means for ABVD  
107 prevention is controlling the primary mosquito vector, *Aedes aegypti*. Existing vector control  
108 interventions, however, have failed to prevent ABV transmission and epidemics[4–6].

109  
110  
111 There is an urgent need to develop evidence-based guidance for the use of new and existing  
112 ABV vector control tools. The evidence-base for vector control against ABVs is weak, despite  
113 considerable government investments in WHO-recommended control of larval habitats  
114 (larviciding, container removal) and ultra-low volume (ULV) insecticide spraying [4,5,7–9]. These  
115 strategies continue to be implemented despite the lack of rigorously generated data from

116 controlled clinical trials demonstrating they reduce ABV infection or disease [6]. The only ABV  
117 intervention with a proven epidemiological impact in a cluster randomized control trial (cRCT)  
118 assessed community mobilization to reduce mosquito larval habitats [10]. A recent test-negative  
119 trial with *Wolbachia*-infected mosquitoes reported a significant reduction of dengue illness in  
120 Indonesia[11].

121  
122 Spatial repellents (SR) are devices that contain volatile active ingredients that disperse in air. The  
123 active ingredients can repel mosquitoes from entering a treated space, inhibit attraction to human  
124 host cues or disrupt mosquito biting and blood feeding behavior, and, thus, interfere with  
125 mosquito-human contact [12–14]. Any of these outcomes reduce the probability of pathogen  
126 transmission. Pyrethroid-based spatial repellents have shown efficacy in reducing malaria  
127 infections in China [15] and Indonesia [16]. There have, however, been no clinical trials  
128 evaluating the protective efficacy of spatial repellents against ABV infection or disease.

129  
130 To generate evidence for public health consideration we conducted a double-blinded, parallel,  
131 cluster-randomized controlled trial (cRCT) to demonstrate and quantify the protective efficacy  
132 (PE) of a transfluthrin-based spatial repellent (SR) to reduce ABV infection incidence over two  
133 years in a human cohort in Iquitos, Peru.

134  
135

## 136 Results

137

138 We report results from the intervention phase of a cRCT, conducted in 26 clusters (13 per arm,  
139 see Methods and SI Section 1.2.1 for randomization scheme) each with approximately 140  
140 households (60 qualifying participants) between August 2016 and March 2019 (**Figure 1-2, SI**  
141 **Section 1.1**). The primary endpoint was ABV seroconversion, as measured by DENV- or ZIKV-  
142 specific neutralizing antibodies, in blood from children  $\geq 2$  years to  $\leq 18$  years collected just prior  
143 to the deployment of the SR intervention, and approximately 1 and 2 years later. The SR  
144 intervention was a transfluthrin passive emanator placed in participating households according to  
145 manufacturer's instructions, 1 product per 9 m<sup>2</sup> and replaced at 15 d intervals (**Figure S1, SI**  
146 **Section 1.3.2**) during the two-year (two-transmission season) study period. Secondary endpoints  
147 were clinically apparent laboratory confirmed ABV disease and indoor female *Ae. aegypti*: 1)  
148 abundance, 2) blood-fed status (proxy for human-biting rates), and 3) parity status (proxy for age-  
149 structure). Participants followed for seroconversion were the 'longitudinal cohort' and those  
150 followed for disease were the 'febrile surveillance cohort'.

151

152

## 153 STUDY POPULATION

154 A total of 2,215 persons were enrolled in the longitudinal cohort. Of these, 1,578 qualifying  
155 participants (individuals who were seronegative or had a monotypic DENV antibody response  
156 when they entered the trial) were included in the ITT analysis for seroconversion (**Figure 3**).  
157 Samples were tested by microneutralization enzyme immunoassay (MNT) for seroconversion to  
158 each DENV serotype and ZIKV (**SI Sections 1.3.3.1 and 1.3.4.1**). Only participants that provided  
159 at least 2 blood samples were included in final analyses. We observed a total of 196 ABV  
160 infections from 754 (1,090 paired samples) qualifying participants in the SR arm and 294 ABV  
161 infections from 824 (1,237 paired samples) qualifying participants in the placebo arm. Baseline  
162 covariates were balanced at both the cluster and individual level (**Table 1**).

163

164 A total of 16,707 participants were followed for clinical disease in the 'febrile surveillance cohort'  
165 through approximately 3 wellness visits per week, of which 16,683 were included in the ITT  
166 analysis (**Figure S2**). Suspected acute ABV cases that provided consent provided acute and  
167 convalescent blood samples and were monitored clinically daily. Acute serum samples were  
168 tested for viral RNA by PCR (DENV and ZIKV; **SI Sections 1.3.3.2-1.3.3.4**) and by ELISA for  
169 DENV IgM (**SI Sections 1.3.3.5,1.3.4.2**) to quantify the secondary endpoint of clinically apparent

170 laboratory confirmation cases of ABV disease. Baseline covariates from the febrile surveillance  
171 cohort were balanced at both the cluster and individual level (**Table S4**).

172

#### 173 INTERVENTION COVERAGE

174 The household participation rate (intervention deployed at some point during the study period) per  
175 cluster (SR and placebo) was of 56.6 % (SD = 10.5%), with slightly more participation in SR  
176 versus placebo clusters (58.8% v 54.5%, p-value = 0.336). In households consenting to receive  
177 intervention (SR or placebo), the mean percentage of days covered by an intervention at the  
178 cluster-level was 81.6% (SD = 3.9), with slightly higher coverage in households assigned to SR  
179 intervention (82.9%) compared to households in the placebo arm (80.3%), albeit insignificant (p-  
180 value = 0.153, **Table S2**, **Figure S3**). For all enrolled households, the mean percentage of days  
181 with an adequate intervention application rate (1 product per 9 m<sup>2</sup>) was 73.6% (SD = 9.1), with  
182 similar rates between SR and placebo clusters (72.7% versus 74.5%, p-value > 0.999, **Table S2**).

183

#### 184 SPATIAL REPELLENT EFFICACY

185 We used survival analysis with proportional hazards model with an exponential distribution  
186 assumption for baseline hazard to estimate a PE (**SI Section 1.5.2.1**). The estimated PE of the  
187 SR intervention was 34.1% (1-sided 95% CI lower limit, 6.9%) (**Table 2**). Reduction in the  
188 arbovirus infection hazard rate was significant at the 5% significance level (Test statistic:  $z=1.98$ ,  
189 1-sided p-value = 0.02). Baseline covariates included in the statistical model on the hazard of  
190 arbovirus infection in qualifying participants were age, which had statistically significant effects on  
191 the hazard of arbovirus infection in qualifying participants, and sex, which did not. Reported age-  
192 and sex-specific hazard rate changes are conditional. Hazard rate increases by 4.6% for every  
193 one-year increase in age. Hazard rate decreases by 4.4% in males relative to females (**Table 2**).  
194 The originally proposed ITT mixed effects logistic regression analysis (**SI Section 1.5.2.2**), which  
195 ignores differential participation duration across qualifying participants, produced a result  
196 consistent with those presented here; i.e., PE > 30% and statistical significance at the 5% level  
197 (**Table 2**).

198

199 The Kaplan-Meier curves of arbovirus infection for qualifying participants by cluster show  
200 considerable between-cluster variation (SR and placebo clusters) as evidenced by the wide  
201 spread of survival curves (Figure 4). For example, there were no arbovirus infections in qualifying  
202 participants in placebo Cluster 7.2, which had only 18 qualifying participants. Conversely, of the  
203 11 qualifying participants who had a duration of at least 15 months between tests in Cluster 8.2, a  
204 total of 5 subjects became infected since their last test. The duration between tests varied by  
205 participant and across clusters (**Figure S4**), resulting in some Kaplan-Meier curves being  
206 estimated beyond two years. In many of those clusters, the only participants that went over two  
207 years between blood sampling were universally found to have had an arboviral infection.

208

209 A Poisson generalized linear regression was used to assess intervention impact on clinical  
210 disease, with an offset for the number of participant-days each participant spent in each cluster.  
211 No covariates were used and due to the small sample size, no random effects were incorporated  
212 (**SI section 1.5.3**). No statistical difference between incidence in the SR and Placebo arms was  
213 detected. Baseline characteristics of covariates included in the analysis of PCR/ELISA confirmed  
214 DENV and ZIKV cases were balanced between SR and placebo arms (**Table S5**). Results from  
215 an ITT fixed effect Poisson generalized linear model indicate the rate ratio is 1.144 with an upper  
216 bound on the 1-sided 95% CI of 1.601. This translates into a 14.4% increase in the rate of  
217 PCR/ELISA confirmed arbovirus infections by SR intervention compared with placebo with the  
218 lower bound of the 1-sided 95% CI of -60.1%. This apparent increase in the intervention area  
219 was not statistically significant at the 5% level (Test statistic:  $z = -0.975$ ), in part because only  
220 96 disease cases were detected, 51 in the SR arm and 45 in the placebo arm during 10,793,792  
221 participant days that appeared balanced between SR and placebo clusters (**Table S4**, **SI Section**  
222 **2.5.2.1**).

223

224 The estimated reduction in adult female *Ae. aegypti* abundance in clusters receiving SR  
225 intervention was 28.6% (1-sided 95% CI lower limit: 24.1%, test statistic:  $z = -9.11$ ) using mixed  
226 effects difference-in-difference (DID) Poisson regression, with factor-level covariates (**Table 3, SI**  
227 **Section 1.5.4**). Baseline mosquito abundance was balanced between treatment arms (**Table S5**)  
228 with post-baseline quantities estimated based on 47,518 and 43,417 household collections in SR  
229 and placebo arms, respectively. Baseline abundance averaged 0.277 (standard deviation [SD]  
230 0.153) and 0.279 (SD 0.122) per house survey in SR and placebo arms, respectively, whereas  
231 post-baseline abundance averaged 0.276 (SD 0.091) and 0.391 (SD 0.142) in the SR and  
232 placebo arms, respectively (**Table 3**). There was strong indication of seasonality, with estimated  
233 z-scores of 6 or greater when comparing each month to the reference month of January (**Table**  
234 **S7**). Overall, abundance trended lower in the SR clusters compared to the placebo clusters after  
235 intervention deployment for the duration of the trial, from 2017-2019 (**Figure 5**). Post-intervention  
236 entomological surveys indicate that this difference disappeared after removal of the intervention  
237 (**Figure S8B**).

238  
239 The estimated reduction in the rate of blood-fed *Ae. aegypti* collected inside houses was 12.4%  
240 (1-sided 95% CI lower limit: 4.2%, test statistic:  $z = -2.430$ ) also using mixed effects DID Poisson  
241 regression (**Table 3**). Baseline abundance of engorged *Ae. aegypti* was balanced across  
242 treatment arms (**Table S5**) with post-baseline quantities estimated based on 9,257 and 11,496  
243 mosquitoes assessed for blood-fed status in SR and placebo arms, respectively. Baseline  
244 abundance of blood-fed mosquitoes averaged 0.593 (standard deviation 0.440) and 0.536  
245 (standard deviation 0.451) per collection in SR and placebo arms, respectively. Post-baseline  
246 rates averaged 0.606 (SD 0.460) and 0.634 (SD 0.447) in SR and placebo arms, respectively.  
247 There was no strong indication of seasonality (**Table S8**).

248  
249 There was no observed intervention effect (**Table 3**) or indication of seasonality (**Table S9**) based  
250 on the parity rate of *Ae. aegypti* females.

#### 251 252 ADVERSE EVENTS (AE) AND SERIOUS ADVERSE EVENTS (SAE)

253 Twenty-nine AEs were reported during the trial (**SI Section 2.8**). Of these, three were associated  
254 with blood draw (vasovagal response, two from SR and one from placebo clusters). The  
255 remaining 26 AEs reflected symptoms consistent with pyrethroid/ transfluthrin exposure.  
256 Reporting of these AEs was higher in the SR clusters (22 of 8,235 subjects: 0.267%) than the  
257 placebo clusters (4 of 8,448 subjects: 0.047%). The relative risk of experiencing a mild adverse  
258 event due to the SR product was 5.6 (95% CI: 1.9-16,  $p = 0.0015$ ). The 26 affected individuals (26  
259 of 16,707 subjects; 0.155%) came from 18 households, often reporting different combinations of  
260 the following symptoms: allergic response with itching and skin irritations ( $n = 19$ ; 15 from SR, four  
261 from placebo clusters), dry mouth/bad taste ( $n = 5$ , from SR clusters only), breathing issues ( $n = 7$ ,  
262 from SR clusters only) including exacerbation of chronic bronchitis or asthma ( $n = 2$ ), and  
263 headaches ( $n = 4$ , from SR clusters only). The total number of AEs reported from longitudinal  
264 subject cohort households during the trial was similarly low (18 of 2,907 households; 0.619%). No  
265 reported SAEs (deaths) were deemed associated with the spatial repellent intervention.

#### 266 267 268 **Discussion**

269  
270 *Aedes*-borne viruses have expanding regions of transmission, cause increasingly frequent  
271 epidemics, and are transmitted by one of the most anthropophilic mosquitoes. There is, therefore,  
272 a growing unmet need for effective ABV disease prevention [9]. Our cRCT provides the first  
273 conclusive statistical evidence from a pre-planned, prospective cluster-randomized, controlled  
274 clinical trial (cRCT) of significant protective efficacy (34.1% hazard estimate) against  
275 human *Aedes*-borne virus (ABV) infection by a chemical-based vector control intervention, in this  
276 case a spatial repellent. The uniqueness of our trial in the realm of *Aedes* vector control is that it  
277 is 1) the first pre-planned, cluster randomized controlled clinical trial 2) with a pre-defined effect

278 size on the primary endpoint of human infection 3) that was appropriately powered to  
279 prospectively quantify and statistically test for a difference in the impact of a chemical intervention  
280 against *Aedes*-borne virus human infection incidence compared to a placebo. Currently used  
281 adult *Aedes* chemical control strategies are not supported by such evidence. Reduced human  
282 infection caused by a reduction in mosquito biting supports development of (1) improved repellent  
283 formulations and (2) enhanced methodologies for broad scale application.

284  
285 PE was detected despite assumed dilution and contamination effects due to participant  
286 movement in and out of study clusters. Unlike a vaccine, SR protected study participants in their  
287 own homes or another protected home within their neighborhood (i.e., Study Cluster), but did not  
288 provide continuous protection after they left treated houses. Our cohort, tested for ABV  
289 seroconversion, was comprised principally of children  $\leq 17$  years of age, most whom attended  
290 schools that have been shown in Iquitos to be of lower risk of *Ae. aegypti* infestation than  
291 residential sites [17]. Our outcome was demonstrated in an operational context, reflecting  
292 complex interactions among ongoing Ministry of Health interventions across the study area,  
293 imperfect coverage at the household-level (rooms closed to intervention, homeowner removal  
294 and/or loss of intervention), <100% household participation within clusters, and the suggestion of  
295 pyrethroid resistance in the local *Ae. aegypti* population [18] (**SI section 2.7**). Reduced risk of  
296 ABV infection was associated with a significant reduction in indoor female *Ae. aegypti* abundance  
297 and blood feeding. Although entomological outcomes were modest, detected effects are  
298 consistent with the expected mode of SR action (i.e., deterrence from house entry and/or  
299 interfering with human-biting) [12,19] and the impact waned after the intervention was removed at  
300 the end of the trial.

301  
302 Our results support SRs as a flexible class of vector control products with positive public health  
303 impact not limited to ABV diseases. Transfluthrin [15] and metofluthrin-based[20] mosquito coils  
304 have been shown to reduce malaria and the same spatial repellent device used in our Iquitos trial  
305 reduced malaria infections in an Indonesia cRCT[16]. The SR product we tested was generally  
306 well tolerated even though it produced mild skin and respiratory irritation, a well know side effect  
307 of pyrethroids. Our trial was the first to quantify these types of adverse events for a chemical  
308 intervention in a double-blinded trial. Our results, therefore, support the potential for SRs to  
309 reduce a variety of vector-borne diseases, augment existing public health efforts and support SRs  
310 as an effective component in vector control intervention strategies. To facilitate implementation  
311 and programmatic scale-up, additional assessments, which have already begun [21–24], are  
312 needed.

313  
314 Our Peru cRCT is one of two trials recommended by the WHO for assessing public health value  
315 and developing global health policy for the SR intervention class [25]. Our study was powered to  
316 detect a 30% reduction in ABV infection risk, not acute ABV disease nor virus infection rates in  
317 mosquitos. During the trial period, dengue prevalence was lower than previous years and a Zika  
318 epidemic occurred in 2016 [26]. This epidemiological uncertainty is typical of ABV transmission,  
319 making powering ABV cRCTs challenging and helps explain why cRCTs with epidemiological  
320 outcomes for ABVs are rare [27]. We used seroconversion as our primary endpoint of PE to  
321 address this challenge. At our Iquitos study site, powering a trial based on clinically apparent ABV  
322 disease would not be logistically feasible.

323  
324 Fully integrating vector control into ABV disease prevention programs will require quantitative  
325 guidance based on quantitative measures of the impact from each intervention component.  
326 Ministries of Health, local to national governments and non-governmental organizations can use  
327 our trial results as an evidence-base for informed application of SRs. Considering the growing  
328 ABV public health threat, difficulties of developing vaccines against multiple viruses and past,  
329 poorly informed vector control failures [6], enhanced ABV disease prevention will benefit greatly  
330 from interventions with proven public health value.

331

## 332 **Materials and Methods**

333

334 This trial is registered with ClinicalTrials.gov, number NCT03553277.

335

### 336 ETHICAL STATEMENT

337 Our study protocol (#NAMRU6.2014.0021, Supplementary Information (SI)) was approved by the  
338 U.S. Naval Medical Research Unit No. 6 (NAMRU-6) Institutional Review Board (IRB), which  
339 includes Peruvian representation and complies with US Federal and Peruvian regulations  
340 governing the protections of human subjects, and the Regional Health Authority (DIRESA), the  
341 local branch of the Peruvian Ministry of Health. IRB authorization agreements were established  
342 between the NAMRU-6, the University of Notre Dame (Sponsor), the University of California at  
343 Davis, and the University of Washington.

344

### 345 TRIAL DESIGN

346 Detailed study methods are provided in the SI.

347

348 Our trial was conducted from June 2015 through March 2019 in the Iquitos and Punchana  
349 Districts of Iquitos, Peru (**Figure 1, SI Section 1.1**). Clusters were selected in January 2015.  
350 Enrollment began June 2015. Participation included: 1) a house census, 2) disease surveillance,  
351 3) annual blood draws, 4) bi-monthly entomological surveys, and 5) intervention application in the  
352 house. Epidemiological monitoring and entomological surveillance lasted from February 2016  
353 through March 2019 (**Figure 2**).

354

355 Our main objective was to demonstrate and quantify the protective efficacy (PE) of a SR in  
356 reducing ABV infection incidence in a human cohort. Qualifying participants were individuals in a  
357 participating house who were seronegative or had a monotypic DENV antibody response when  
358 they entered the trial. Assuming the probability of seroconversion for seronegative or monotypic  
359 individuals was 10% with a coefficient of variation of 0.25, and an alpha of 5%, we estimated we  
360 would need 26 clusters (13 per arm) with approximately 60 qualifying individuals to achieve a  
361 power of 80% to detect a reduction in the odds of 30%.

362

363 The primary endpoint was ABV seroconversion, as measured by DENV- or ZIKV-specific  
364 neutralizing antibodies, in blood from children  $\geq 2$  years to  $\leq 18$  years. To increase the pool of  
365 baseline seronegative participants, we expanded screening to  $\geq 18$  years. Secondary endpoints  
366 were clinically apparent laboratory confirmed ABV disease and indoor female *Ae. aegypti*: 1)  
367 abundance, 2) blood-fed status (proxy for human-biting rates), and 3) parity status (proxy for age-  
368 structure). Participants followed for seroconversion were the 'longitudinal cohort' and those  
369 followed for disease were the 'febrile surveillance cohort'.

370

### 371 RANDOMIZATION AND INTERVENTION

372 A total of 26 clusters (13 per arm) each with approximately 140 households (60 qualifying  
373 participants) were randomly allocated in August 2016 to receive SR or placebo intervention by the  
374 external statistician serving on the Data Safety Monitoring Board (DSMB) using a random number  
375 generator (<https://www.random.org>) (**SI Section 1.2.1**). Investigators, research staff, and study  
376 participants were blinded to cluster allocation. Our intervention was a transfluthrin passive  
377 emanator designed and produced by SC Johnson (Racine, WI), replaced at 2-week intervals, as  
378 described previously (**Figure S1, SI Section 1.3.2**)[16]. Our trial was specifically designed to  
379 evaluate the protective efficacy of the first in class spatial repellent product prototype to enable  
380 WHO assessment for public health value of the spatial repellent product class. Spatial repellent  
381 products are not yet recommended by WHO for inclusion into programmatic vector control  
382 strategies. We selected the SCJ manufactured, transfluthrin-based passive emanator because it  
383 represents the first in class prototype of a spatial repellent under WHO public health value  
384 assessment[28]. The spatial repellent intervention used in our study is the same intervention  
385 evaluated against malaria infections in Sumba Indonesia[16]. Spatial repellent and placebo



386 intervention had identical packaging and were deployed in houses by study personnel using a  
387 blinded coding scheme. The placement of the intervention followed manufacturer specifications  
388 for indoor use conditions.

### 389 390 SEROCONVERSION AND DISEASE SURVEILLANCE

391 Recruitment for the longitudinal cohort focused on children because they were likely to be  
392 antibody test-negative or monotypic at baseline than adults, which would facilitate interpretation  
393 of laboratory assays, and less mobile than adults[29], thus spending more time in their houses or  
394 their assigned cluster. Baseline blood samples were obtained within 2 weeks before or after initial  
395 intervention deployment. As new families moved into the study area, they were recruited to  
396 participate, resulting in longitudinal participant enrollment throughout the interval between  
397 Baseline (B), First (F), and Second/Final (S) longitudinal blood draws (**Figure 3**). Samples were  
398 tested by microneutralization enzyme immunoassay (MNT) for seroconversion to each DENV  
399 serotype and ZIKV (**SI Sections 1.3.3.1 and 1.3.4.1**). Only participants that provided at least 2  
400 blood samples were included in final analyses.

401  
402 The febrile surveillance cohort was recruited by nurse technicians during door-to-door wellness  
403 checks starting with the first week of intervention deployment. Suspected cases exhibited axillary  
404 temperature of  $\geq 37.5^{\circ}\text{C}$  or, for suspected ZIKV infection, absence of fever but presence of rash,  
405 arthralgia, arthritis, or non-purulent conjunctivitis for  $\leq$  five days. Participants meeting these  
406 criteria provided acute and convalescent (14–21 days later) serum samples and were monitored  
407 clinically daily. Acute serum samples were tested for viral RNA by PCR (DENV and ZIKV; **SI**  
408 **Sections 1.3.3.2-1.3.3.4**) and by ELISA for DENV IgM (**SI Sections 1.3.3.5,1.3.4.2**).

### 409 410 ENTOMOLOGICAL ENDPOINTS

411 Indoor Prokopack aspirations [30] were conducted in all consented homes at time of first  
412 intervention deployment and subsequent intervention replacement; i.e., two-week intervals. Adult  
413 mosquitoes were transported to the NAMRU-6 Iquitos laboratory, sedated at  $4^{\circ}\text{C}$ , identified to  
414 species and sex, counted by date and house. Up to 30 female *Ae. aegypti* per household per  
415 collection were examined for blood meal status and scored as unfed, blood-fed (fully engorged,  
416 half-engorged, or trace amounts), or gravid [31]. These female mosquitoes were then dissected  
417 to determine their parity status (parous, nulliparous, or gravid) (**SI Section 1.3.5.1**). Standard  
418 insecticide resistance assays were used to assess vector susceptibility to transfluthrin one-year  
419 into the trial (**SI Section 1.3.5.2**).

### 420 421 SAFETY MONITORING

422 Adverse events (AEs) and serious adverse events (SAEs) were actively collected throughout the  
423 trial during surveillance follow-up and entomological surveys (**SI Section 1.3.6**). Reported AEs  
424 were investigated by study staff and appropriate care was recommended by a study physician  
425 within 24 hours. Safety reporting to the NAMRU-6 IRB was managed by UC Davis in accordance  
426 with the approved protocol. Quarterly reports summarizing reported AEs and SAEs were  
427 reviewed by the DSMB for trial safety assessment.

### 428 429 STATISTICAL ANALYSIS

430 Details of our analytical approach are provided in the statistical analysis plan (**SAP**) and **SI**  
431 **Section 1.5**. All analyses were conducted by RCR using R 3.6.1 (R Core Team)[32] and the  
432 lme4[33] and survival[34] packages. No correction for multiple testing was performed for  
433 secondary endpoint analyses and, as such, in accordance with CONSORT guidelines, in those  
434 cases we do not present p-values.

435  
436 The choice of the investigators to select and report a one-sided p-value and corresponding one-  
437 sided confidence interval is based on the underlying assumption associated with the intervention;  
438 i.e., the spatial repellent will not increase risk/harm (disease) over the standard of care. The  
439 statistical translation is that we are testing to see if a) the intervention is no better than the

440 standard of care or b) the intervention is better than the standard of care (superior). As this is a  
441 one-sided test of superiority, we present one-sided test results. We also provide the null and  
442 alternative hypotheses, test statistic, and its assumed distribution to provide readers information  
443 to interpret the p-value and confidence interval.

444  
445 The primary analysis was an intent-to-treat (ITT) assessment of ABV seroconversion for all  
446 qualifying participants per treatment assignment who were >2 years to <18 years of age. Due to  
447 the rolling nature of enrollment, we used a survival analysis with a proportional hazards model  
448 and exponential distribution assumption for the baseline hazard (i.e., constant baseline hazard  
449 through time) and a frailty component to account for correlation within clusters. If  $h(t_{ij} | x_{ij})$  is the  
450 hazard rate of the  $j^{th}$  individual in the  $i^{th}$  cluster with covariate values  $x_{ij}$  then this individual's  
451 hazard rate of an arbovirus infection can be written as:

$$h(t_{ij} | x_{ij}) = h_0(t_{ij}) \cdot \exp(\beta^T x_{ij} + W_i)$$

452  
453 where  $W_i \sim N(0, \sigma_c^2)$  is the random effect of the  $i^{th}$  cluster. Covariates included age, sex, and  
454 treatment status (SR or placebo). PE was estimated as  $PE = (1 - \exp(\hat{\beta})) \times 100\%$ , where  $\hat{\beta}$  is  
455 the estimated regression coefficient for the intervention group and  $\exp(\hat{\beta})$  is the estimated hazard  
456 ratio (HR) between SR and placebo. The null hypothesis of PE = 0% is equivalent to  $\beta = 0$ , which  
457 is tested by Wald's test  $z = \hat{\beta}/s$ , where  $s$  is the estimated standard error of  $\hat{\beta}$ , at the 1-sided  
458 significance level of 5%.

459  
460 A Poisson generalized linear regression was used to assess intervention impact on clinical  
461 disease, with an offset for the number of participant-days each participant spent in each cluster.  
462 No covariates were used and due to the small sample size, no random effects were incorporated.

463  
464 Indoor adult female *Ae. aegypti* abundance, blood-fed rates, and parity were tested through  
465 difference-in-difference Poisson generalized linear mixed models. Collections conducted in 2016  
466 were defined as 'baseline' and collections conducted in 2017 and 2018 were estimated as 'post-  
467 baseline'. Each analysis accounted for month of year and year as fixed effects and contained a  
468 random effect by cluster. Model formulation details are presented in **SI Sections 1.5.4-1.5.6**.

469  
470 The primary analysis conducted differs from that in the original SAP (**SI SAP**). Procedures called  
471 for yearly blood draws from children. To increase the number of qualifying participants, we  
472 expanded the age range of the longitudinal cohort to all ages  $\geq 2$  yrs. The rolling enrollment  
473 resulted in substantial variation in time intervals between blood draws. Simple logistic regression,  
474 therefore, was inadequate. The decision to alter the primary analysis was discussed and agreed  
475 upon by the study statistician and the external DSMB statistician before outputs were unblinded  
476 to the DSMB statistician.

477  
478  
479

## 480 **Acknowledgments and Funding Sources**

481  
482 We extend sincere appreciation to DSMB members: Dennis Shanks, Chris Drakeley, and Neal  
483 Alexander for assurances on data integrity and safety assessments. We thank the World Health  
484 Organization Vector Control Advisory Group (WHO VCAG) for their comments during project  
485 assessments. We are grateful for the efforts of Marianne Kent, Program Coordinator at the  
486 University of Notre Dame, for her administrative, and logistical support of the program, as well as  
487 Brett Fox of the University of Notre Dame Center for Research Computing for assisting with  
488 central database development for data verification. We thank Kristina Davis and Matthew Sisk of  
489 the University of Notre Dame Center for Research Computing and Hesburgh Libraries,  
490 respectively, for their assistance in graphic development. We acknowledge Audrey Lenhart of the  
491 Centers for Disease Control and Prevention (CDC) in Atlanta, GA USA and J. Kevin Baird of the

492 Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia and Nuffield Department of Medicine,  
493 Centre for Tropical Medicine, University of Oxford, Oxford, United Kingdom for their role on the  
494 Scientific Advisory Committee.

495  
496 We are grateful to SC Johnson for providing integral industry and product expertise including the  
497 independent funding of the development, manufacturing, delivery, and shipment of the spatial  
498 repellent and placebo products used in the study. SC Johnson provided expertise in ensuring  
499 intervention quality, storage, application and disposal assurances throughout the trial.

500  
501 We thank the residents of Iquitos for their support and participation in this study and willingness to  
502 allow this study to be conducted in their homes and community. We greatly appreciate support of  
503 the Loreto Regional Health Department, including Drs. Hugo Rodriguez-Ferruci, Christian Carey,  
504 Carlos Alvarez, and Lic. Wilma Casanova Rojas, who facilitated our work in Iquitos. We thank the  
505 Naval Medical Research Unit-6 (NAMRU-6) Virology and Emerging Infections Department (VEID)  
506 leadership who provided institutional support, IRB guidance, and support supervising field staff.  
507 We appreciate the commentary and advice provided by the NAMRU-6 IRB and Research  
508 Administration Program for the duration of this study. We thank the NAMRU-6 VEID field team  
509 which provided daily support through the duration of the project and without whom the recruitment  
510 of acute dengue cases would not have been possible. We thank Cecilia Gonzales, Gloria Talledo,  
511 and Gabriela Vasquez de la Torre for their administrative support of the project.

512  
513 **Financial disclosure statement:** This study was funded by the Bill and Melinda Gates  
514 Foundation (BMGF) to the University of Notre Dame (Grant# OPP1081737). Further support was  
515 provided by the Defense Threat Reduction Agency (DTRA), Military Infectious Disease Research  
516 Program (MIDRP, S0520\_15\_LI and S0572\_17\_LI), and the U.S. National Institute of Allergy and  
517 Infectious Diseases (NIH/NIAID) award number P01 AI098670. SC Johnson used internal  
518 company financial resources for the development, manufacturing, delivery, and shipment of the  
519 intervention (SR and placebo) used in the study.

520

521

522

## 523 **References**

524

525 1. Murray CJL, Barber RM, Foreman KJ, Ozgoren AA, Abd-Allah F, Abera SF, et al. Global,  
526 regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and  
527 healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological  
528 transition. *Lancet*. 2015;386: 2145–2191.

529

530 2. Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, et al. The  
531 global burden of dengue: an analysis from the Global Burden of Disease Study 2013. *Lancet Infect Dis*. 2016;16: 712–723.

532

533 3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global  
distribution and burden of dengue. *Nature*. 2013;496: 504–507.

534

535 4. Bowman LR, Donegan S, McCall PJ. Is Dengue Vector Control Deficient in Effectiveness or  
Evidence?: Systematic Review and Meta-analysis. *PLoS Negl Trop Dis*. 2016;10: e0004551.

536


537 5. Horstick O, Runge-Ranzinger S, Nathan MB, Kroeger A. Dengue vector-control services:  
538 how do they work? A systematic literature review and country case studies. *Trans R Soc  
Trop Med Hyg*. 2010;104: 379–386.

539


540 6. Achee NL, Gould F, Perkins TA, Reiner RC Jr, Morrison AC, Ritchie SA, et al. A critical  
assessment of vector control for dengue prevention. *PLoS Negl Trop Dis*. 2015;9: e0003655.

- 541 7. Parks W, Lloyd L. Planning social mobilization and communication for dengue fever  
542 prevention and control. Geneva: WHO; 2004.
- 543 8. Esu E, Lenhart A, Smith L, Horstick O. Effectiveness of peridomestic space spraying with  
544 insecticide on dengue transmission; systematic review. *Trop Med Int Health*. 2010;15: 619–  
545 631.
- 546 9. Morrison AC, Zielinski-Gutierrez E, Scott TW, Rosenberg R. Defining challenges and  
547 proposing solutions for control of the virus vector *Aedes aegypti*. *PLoS Med*. 2008;5: e68.
- 548 10. Andersson N, Nava-Aguilera E, Arostegui J, Morales-Perez A, Suazo-Laguna H, Legorreta-  
549 Soberanis J, et al. Evidence based community mobilization for dengue prevention in  
550 Nicaragua and Mexico (Camino Verde, the Green Way): cluster randomized controlled trial.  
551 *BMJ*. 2015;351: h3267.
- 552 11. Utarini A, Indriani C, Ahmad RA, Tantowijoyo W, Arguni E, Ansari MR, et al. Efficacy of  
553 Wolbachia-infected mosquito deployments for the control of dengue. *N Engl J Med*.  
554 2021;384: 2177–2186.
- 555 12. Achee NL, Bangs MJ, Farlow R, Killeen GF, Lindsay S, Logan JG, et al. Spatial repellents:  
556 from discovery and development to evidence-based validation. *Malar J*. 2012;11: 164.
- 557 13. World Health Organization, WHO Pesticide Evaluation Scheme. Guidelines for efficacy  
558 testing of spatial repellents. Genève, Switzerland: World Health Organization; 2013.
- 559 14. WHO | Vector Control Advisory Group. 2020 [cited 26 Nov 2020]. Available:  
560 <https://www.who.int/vector-control/vcag/en>
- 561 15. Hill N, Zhou H, Wang P, Guo X, Carneiro I, Moore SJ. A household randomized, controlled  
562 trial of the efficacy of 0.03% transfluthrin coils alone and in combination with long-lasting  
563 insecticidal nets on the incidence of *Plasmodium falciparum* and *Plasmodium vivax* malaria  
564 in Western Yunnan Province, China. *Malaria Journal*. 2014. p. 208. doi:10.1186/1475-2875-  
565 13-208
- 566 16. Syafruddin D, Asih PBS, Rozi IE, Permana DH, Nur Hidayati AP, Syahrani L, et al. Efficacy  
567 of a Spatial Repellent for Control of Malaria in Indonesia: A Cluster-Randomized Controlled  
568 Trial. *Am J Trop Med Hyg*. 2020. doi:10.4269/ajtmh.19-0554
- 569 17. Morrison AC, Sihuincha M, Stancil JD, Zamora E, Astete H, Olson JG, et al. *Aedes aegypti*  
570 (Diptera: Culicidae) production from non-residential sites in the Amazonian city of Iquitos,  
571 Peru. *Ann Trop Med Parasitol*. 2006;100 Suppl 1: S73–S86.
- 572 18. Palomino-Salcedo M. [Estado de susceptibilidad de la población natural de *Aedes aegypti* a  
573 los insecticidas en Punchana-Iquitos, Región Loreto (Noviembre 2014). Instituto Nacional de  
574 Salud, Peru; 2014.
- 575 19. Norris E, Coats J. Current and future repellent technologies: The potential of spatial  
576 repellents and their place in mosquito-borne disease control. *Int J Environ Res Public Health*.  
577 2017;14: 124.
- 578 20. Syafruddin D, Bangs MJ, Sidik D, Elyazar I, Asih PBS, Chan K, et al. Impact of a spatial  
579 repellent on malaria incidence in two villages in Sumba, Indonesia. *Am J Trop Med Hyg*.  
580 2014;91: 1079–1087.


- 581 21. Liverani M, Charlwood JD, Lawford H, Yeung S. Field assessment of a novel spatial repellent  
582 for malaria control: a feasibility and acceptability study in Mondulkiri, Cambodia. *Malar J*.  
583 2017;16: 412.
- 584 22. Masalu JP, Finda M, Okumu FO, Minja EG, Mmbando AS, Sikulu-Lord MT, et al. Efficacy  
585 and user acceptability of transfluthrin-treated sisal and hessian decorations for protecting  
586 against mosquito bites in outdoor bars. *Parasit Vectors*. 2017;10: 197.
- 587 23. Paz-Soldan VA, Plasai V, Morrison AC, Rios-Lopez EJ, Guedez-Gonzales S, Grieco JP, et  
588 al. Initial assessment of the acceptability of a Push-Pull *Aedes aegypti* control strategy in  
589 Iquitos, Peru and Kanchanaburi, Thailand. *Am J Trop Med Hyg*. 2011;84: 208–217.
- 590 24. Jumbam DT, Stevenson JC, Matoba J, Grieco JP, Ahern LN, Hamainza B, et al. Knowledge,  
591 attitudes and practices assessment of malaria interventions in rural Zambia. *BMC Public*  
592 *Health*. 2020;20: 216.
- 593 25. World Health Organization. The evaluation process for vector control products. World Health  
594 Organization; 2017. Report No.: WHO/HTM/GMP/2017.13. Available:  
595 <https://apps.who.int/iris/handle/10665/255644>
- 596 26. [cited 2 Dec 2020]. Available: [https://www.paho.org/hq/dmdocuments/2017/2017-phe-zika-](https://www.paho.org/hq/dmdocuments/2017/2017-phe-zika-situation-report-per.pdf)  
597 [situation-report-per.pdf](https://www.paho.org/hq/dmdocuments/2017/2017-phe-zika-situation-report-per.pdf)
- 598 27. Anders KL, Cutcher Z, Kleinschmidt I, Donnelly CA, Ferguson NM, Indriani C, et al. Cluster-  
599 Randomized Test-Negative Design Trials: A Novel and Efficient Method to Assess the  
600 Efficacy of Community-Level Dengue Interventions. *Am J Epidemiol*. 2018;187: 2021–2028.
- 601 28. Overview of intervention classes and prototype/products under Vector Control Advisory  
602 Group (VCAG) review for assessment of public health value 1. [cited 10 Mar 2022].  
603 Available: [https://apps.who.int/iris/bitstream/handle/10665/274451/WHO-CDS-VCAG-](https://apps.who.int/iris/bitstream/handle/10665/274451/WHO-CDS-VCAG-2018.03-eng.pdf)  
604 [2018.03-eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/274451/WHO-CDS-VCAG-2018.03-eng.pdf)
- 605 29. Vazquez-Prokopec GM, Bisanzio D, Stoddard ST, Paz-Soldan V, Morrison AC, Elder JP, et  
606 al. Using GPS technology to quantify human mobility, dynamic contacts and infectious  
607 disease dynamics in a resource-poor urban environment. *PLoS One*. 2013;8: e58802.
- 608 30. Vazquez-Prokopec GM, Galvin WA, Kelly R, Kitron U. A new, cost-effective, battery-powered  
609 aspirator for adult mosquito collections. *J Med Entomol*. 2009;46: 1256–1259.
- 610 31. Gunning CE, Okamoto K, Astete H, Vasquez GM, Erhardt E, Del Aguila C, et al. Efficacy of  
611 *Aedes aegypti* control by indoor Ultra Low Volume (ULV) insecticide spraying in Iquitos,  
612 Peru. *PLoS Negl Trop Dis*. 2018;12: e0006378.
- 613 32. R Core Team. R: A language and environment for statistical computing. R Foundation for  
614 Statistical Computing. Vienna, Austria; 2019. Available: <http://www.R-project.org/>.
- 615 33. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models using lme4.  
616 arXiv [stat.CO]. 2014. Available: <http://arxiv.org/abs/1406.5823>
- 617 34. Therneau TM. A Package for Survival Analysis in S. version 2.38. Comprehensive R Archive  
618 Network (CRAN); 28 Sep 2015 [cited 19 Jan 2021]. Available: [http://cran.r-](http://cran.r-project.org/package=survival)  
619 [project.org/package=survival](http://cran.r-project.org/package=survival)



**Figure 1.** Location of 26 study clusters in Iquitos and Punchana Districts, Loreto Department, Iquitos, Peru. Each cluster consisted of ca. 140 households with an average distance of 300m between clusters.




**Figure 2.** Study timeline. Top panel: Human blood-sampling, disease surveillance, and entomological monitoring in relation to deployment of the spatial repellent intervention. Bottom panel: Intervention roll-out between August-December 2016 by cluster. Horizontal numbers correspond to cluster numbers shown in Figure 1.




**Figure 3.** Allocation and follow-up of the longitudinal cohort population during three blood collection periods (Baseline [B], First [F] and Second/Final [S]). The majority (62%) of participants provided samples at each collection period, whereas some only participated during year 1 (B-F) or year 2 (F-S). Participants with a single sample were lost to follow-up and four individuals moved or had two houses located in the spatial repellent and placebo clusters are shown as removed at the baseline period for clarity.





**Figure 4.** Kaplan-Meier curves of arbovirus infection for 13 spatial repellent (SR) and 13 placebo clusters in qualifying participants measured by seroconversion (primary endpoint) by cluster. Panel A, Hazard rates by individual cluster. Panel B, Aggregated hazard rate.



**Figure 5.** Mean densities of adult female *Aedes aegypti* collected per household survey in 13 spatial repellent (SR) and 13 placebo clusters by study month. Shaded areas represent the 95% Confidence Interval around the mean.

**Table 1.** Summary of baseline characteristics, for qualifying participants of the intent-to-treat (ITT) longitudinal cohort population in spatial repellent (SR) and placebo arms. Qualifying participants were defined as individuals in a participating house that were seronegative or had a monotypic DENV antibody response when they entered the trial.

<b>Individual-Level</b>		
Variable	SR (n=898)	Placebo (n=952)
Age in years (mean±sd) (min, max)	10.88±4.62 (2, 47)	10.19±4.39 (2, 22)
Sex (% male)	51.6%	55.0%
Duration in years between samples (mean±sd) (min, max)	1.15±0.42 (0.02, 2.29)	1.16±0.43 (0.01, 2.35)
No. qualifying participant observations	1,090	1,237
No. of arbovirus seroconversions	196	294
<b>Cluster-Level</b>		
Variable	SR (n=13)	Placebo (n=13)
Cluster population (mean±sd) (min, max)	58.2±30.4 (21, 124)	73.5±35.3 (12, 132)
Baseline susceptibility (mean±sd) (min, max)	81.0%±12.8% (54.7%, 98.1%)	84.9%±6.3% (73.3%, 92.5%)

**Table 2.** Protective efficacy (PE) estimates from intent to treat (ITT) analyses for the spatial repellent intervention against *Aedes*-borne virus infection in qualifying participants measured by seroconversion (primary endpoint), including covariate effects.

ITT analysis	Hazard rate ratio (95% CI)	PE (%) (95% CI)	One-sided p-value	Covariate	Odds ratio (95% CI)	Two-sided p-value
Survival analysis	0.659 (-∞, 0.931)	34.1 (6.9, ∞)	0.024			
				Age	1.046 (1.029-1.063)	6.8 x 10 <sup>-6</sup>
				Male	0.956 (0.821-1.112)	0.62
ITT analysis	Odds ratio (95% CI)	PE (%) (95% CI)	One-sided p-value	Covariate	Odds ratio (95% CI)	Two-sided p-value
Odds reduction	0.547 (-∞, 0.883)	45.3 (11.7, ∞)	0.019			
				Age	1.071 (1.042-1.100)	6.9 x 10 <sup>-7</sup>
				Male	0.950 (0.767-1.177)	0.64
Odds reduction on including 9–15-month sampling intervals	0.577 (-∞, 0.879)	42.3 (12.1, ∞)	0.016			
				Age	1.065 (1.028-1.103)	0.0005
				Male	0.970 (0.767-1.299)	0.779

**Table 3.** Rate reduction summary of indoor adult female *Aedes aegypti* abundance, blood-fed female abundance, and parity rates (secondary endpoints) for primary (ITT) and secondary analyses (PP). No correction for multiple testing was performed for secondary endpoint analyses and, as such, in accordance with CONSORT guidelines p-values are not presented.

Indicator	Statistics	2016 Baseline <sup>1</sup>		Cluster-specific Baseline <sup>2</sup>	
		ITT	PP	ITT	PP
Indoor adult female <i>Aedes aegypti</i> abundance	Rate ratio (95% one-sided CI)	0.714 (-∞, 0.759)	0.737 (-∞, 0.784)	0.599 (-∞, 0.633)	0.607 (-∞, 0.641)
	Rate reduction (%) (95% one-sided CI)	28.6 (24.1, ∞)	26.3 (16.2, ∞)	40.1 (36.7, ∞)	39.3 (35.9, ∞)
Blood-fed female <i>Aedes aegypti</i> abundance	Rate ratio (95% one-sided CI)	0.876 (-∞, 0.958)	0.876 (-∞, 0.958)	0.908 (-∞, 0.985)	0.929 (-∞, 1.06)
	Rate reduction (%) (95% one-sided CI)	12.4 (4.2, ∞)	12.4 (4.2, ∞)	9.20 (1.49, ∞)	7.10 (-6, ∞)
<i>Aedes aegypti</i> parity rate	Rate ratio (95% one-sided CI)	0.922 (-∞, 1.057)	0.921 (-∞, 1.056)	0.928 (-∞, 1.058)	0.909 (-∞, 0.986)
	Rate reduction (%) (95% one-sided CI)	7.75 (-5.70, ∞)	7.87 (-5.60, ∞)	7.24 (-5.80, ∞)	9.10 (-1.2, ∞)

<sup>1</sup> Intent to treat (ITT, primary analysis) and per protocol (PP, secondary analysis) mixed effects difference-in-difference (DID) Poisson regression specifying measurements made throughout 2016 as 'baseline', with post-2016 measurements as 'post-baseline.' PP analysis only considering houses with SR application rates meeting manufactures specifications  $\geq 75\%$  of the days between sequential blood sampling (designated PP-1).

<sup>2</sup> ITT and PP mixed effects DID Poisson regression specifying measurements made in 2016 up to the first date of intervention deployed in each cluster as 'baseline' with all measurements following that date as 'post-baseline' for that cluster, even for houses that did not enroll until 2017 or later. PP analysis only considering houses with SR application rates meeting manufactures specifications  $\geq 75\%$  of the days between sequential blood sampling (designated PP-1).